BioVie’s Bezisterim Shows Trend Toward Symptom Improvement in Phase 2 Long COVID Trial
Bitget2026/10/26 12:10- BioVie will present Phase 2 ADDRESS-LC results for bezisterim in Long COVID on November 5, 2026, at the RECOVER-TLC workshop.
- Bezisterim showed a consistent trend toward improvement versus placebo across most patient-reported symptoms and objective measures.
- Patients with greater baseline symptom severity benefited most, with statistically significant improvements in measures corresponding to their most pronounced symptoms.
- Safety and tolerability were similar to placebo.
- The findings provide a foundation for designing a confirmatory Phase 3 study.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Ripple's Dubai Event Presence Gets High-Profile Boost From Emirates Chairman
Signal of a rebound? Goldman Sachs US stock panic index reaches "extreme levels"
Goldman Sachs Volatility Panic Index surged to 9.57, approaching its maximum value, with the largest single-day increase ranking third in history, and the combined two-day volatility setting a new record. Historical data shows that after this index has exceeded the 9.5 threshold 15 times, the S&P 500 has seen an average three-month gain of 4.6% with a success rate of 80%. However, Goldman Sachs traders warn that forced liquidations have not yet fully cleared, and the market is still searching for a bottom, but opportunities on the other side are becoming increasingly difficult to ignore.
SpaceX (SPCX.US) undergoes board changes: Google executive departs, Tesla merger evaluation underway.
SpaceX (SPCX.US) announced on Friday that Don Harrison has resigned from the company's board of directors.
Crypto prices
More
